Therapy of NMO spectrum disorders

Area of Science:

• Neuroimmunology
• Autoimmune Disorders
• Central Nervous System Diseases

Background:

• Neuromyelitis Optica (NMO) is a severe autoimmune demyelinating disease of the central nervous system.
• It is often linked to aquaporin-4 (AQP4) autoantibodies and characterized by optic neuritis and myelitis.
• NMO Spectrum Disorder (NMOSD) includes seronegative patients or those not meeting NMO criteria, treated similarly.

Purpose of the Study:

• To outline current treatment strategies for acute relapses and long-term relapse prevention in NMO and NMOSD.
• To discuss the efficacy and limitations of various immunosuppressive agents used for relapse prevention.
• To highlight the need for further research and consensus on treatment duration and management.

Main Methods:

• Review of established treatment protocols for acute NMO/NMOSD relapses.
• Summary of evidence for immunosuppressive therapies in relapse prevention.
• Discussion of clinical experience and expert opinion on long-term management.

Main Results:

• Acute relapses are treated with intravenous methylprednisolone and potentially plasma exchange, followed by oral steroids.
• Several immunosuppressive agents (azathioprine, rituximab, mycophenolate mofetil, methotrexate, mitoxantrone) show efficacy in preventing relapses.
• Monotherapy may be insufficient for some patients, necessitating treatment escalation or combination therapy.

Conclusions:

• Current treatment paradigms for NMO/NMOSD focus on managing acute attacks and preventing future relapses.
• While effective agents exist, a lack of randomized controlled trials necessitates careful consideration of treatment choices and duration.
• Long-term management requires balancing efficacy against the risks of immunosuppressive therapy toxicity, with a general recommendation of 2-3 years relapse-free period.